Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Hexyon vaccine, Hexaxim Vaccine, Hexyon®, Hexacima®
Hexaxim · 1 trial · 6 indications
Solicited injection site reactions: tenderness, erythema, and swelling (and extensive limb swelling for booster dose). Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite loss, and irritability
| Arm | Type | Description |
|---|---|---|
| DTaP-IPV-HB-PRP~T Vaccine | EXPERIMENTAL | All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP\~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age). |
| Name | Type | Description |
|---|---|---|
| Hexaxim® | BIOLOGICAL | DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged 61 to 91 days on the day of the first study visit * Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥2.5 kg * Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if ...
Hexaxim is a combined vaccine developed by Sanofi for protection against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. It is given as a primary vaccination series in infants, followed by a booster dose, and is studied in the infectious disease therapeutic area.
Hexaxim is developed by Sanofi, which trades under the ticker SNY. Sanofi Pasteur, the company's vaccines unit, conducted the clinical program for the product.
Hexaxim has been evaluated in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The program enrolled 354 participants in total.
Hexaxim has been studied in the completed Phase 3 trial NCT02428491, which assessed immunogenicity and safety of the combined vaccine given as a three-dose primary series at 2, 3, and 4 months of age, followed by a booster dose at 16 to 17 months, in Vietnamese infants.
Yes, Hexaxim is also known as Hexyon vaccine. Other names used for the same product include Hexaxim Vaccine and Hexaxim with a registered trademark symbol. These names refer to the same Sanofi combined vaccine.